Search

Your search keyword '"Schneeweis, Christian"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Schneeweis, Christian" Remove constraint Author: "Schneeweis, Christian"
32 results on '"Schneeweis, Christian"'

Search Results

1. Non-canonical functions of SNAIL drive context-specific cancer progression

3. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment

5. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer

6. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer

8. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction.

11. Corrigendum to “A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer” [Bioorgan. Chem. 119 (2022) 105505]

12. MTOR inhibitor-based combination therapies for pancreatic cancer

13. The Role of FRA1 and SUMOylation in Pancreatic Cancer

14. Die Rolle von FRA1 und SUMOylierung im Pankreaskarzinom

15. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer

16. Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype

17. RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells

18. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition

19. Abstract 2475: Differential sensitivity of mouse PDAC KrasG12Dcells to Ref-1/APE1 redox signalling inhibitors: Role of NFkB as a primary target of Ref-1/APE1 inKrasdriven pancreatic ductal adenocarcinoma

20. Targeting the ubiquitin���proteasome system in a pancreatic cancer subtype with hyperactive MYC

21. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

22. Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC

24. Abstract 1793: Interaction of MYC and SUMOylation machinery in an aggressive pancreatic cancer subtype

25. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

27. Adaptive rewiring of oncogenic signalling upon MTOR deletion in pancreatic cancer

29. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

30. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—A connection to licensing nodes.

31. KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening.

32. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

Catalog

Books, media, physical & digital resources